Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  vismodegib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 32 for your search:
Start Over
VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Phase: Phase IV
Type: Treatment
Status: Enrolling by invitation
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2014.022, HUM00082579, NCT02436408
Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2010-01737, CDR0000670590, 2009-0473, 8384, N01CM00039, N01CM62202, P30CA016672, U01CA062461, U01CA062491, MDA-2009-0473, NCT01163084
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01412, CDR0000680558, MSKCC-10049, 10-049, 8406, U01CA069856, P30CA008748, N01CM62206, NCT01154452
Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 19 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03099, NCI 8395, 09-149-B, 8395, P30CA014599, U01CA069852, NCT01174264
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SHH4429g, NCT00636610
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SHH4489g, NCT00739661
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SHH4476g, GO01541, NCT00833417
Cisplatin and Etoposide With or Without Vismodegib or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01917, ECOG-E1508, CDR0000640898, E1508, U10CA021115, U10CA180820, NCT00887159
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 22 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03020, PBTC-025B, U01CA081457, NCT00939484
The Purpose of This Study is to Determine The Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 35 to 75
Sponsor: Other
Protocol IDs: 2009-026, SHH-4685s, NCT00957229
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02922, CDR0000654829, ABTC-0904, U01CA137443, 0904, NCT00980343
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01425, 09-0356, CDR0000655339, NYU 09-0356, 8376, N01CM00038, N01CM00071, P30CA016087, N01CM00070, NYCC-09-0356, NCT00982592
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 21 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01454, 8418, UCCRC-8418, CDR0000655378, 09-068, N01CM00071, P30CA014599, N01CM00038, NCT01064622
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-03746, UMCC 2010-003, 8417, P30CA046592, 2010-003, NCT01143415, NCT01195415
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SHH4812g, GS01354, NCT01201915
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 3 to 21
Sponsor: NCI
Protocol IDs: NCI-2011-02546, CDR0000688451, PBTC-032, U01CA081457, NCT01239316
Vismodegib in Treating Patients With Advanced Chondrosarcomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02564, CHONDROG, CDR0000691728, IB-CHONDROG, 8408, NCI-8408-CHONDROG, NCT01267955
STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO25616, 2011-000195-34, NCT01367665
Vismodegib for Treatment of Basal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 5110325, NCT01543581
Trial Comparing the Effects of Intermittent Vismodegib Versus Photodynamic Therapy in Patients With Multiple Basal Cell Carcinomas
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2011-077, ML28244, NCT01556009
A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO28295, 2012-003305-10, NCT01815840
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GO28852, 2013-001570-14, NCT01880437
A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML28726, NCT01898598
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 3 to 21
Sponsor: NCI
Protocol IDs: NCI-2009-01180, CDR0000631677, PBTC-025, U01CA081457, NCT00822458
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CDR0000585468, JHOC-J06131, GENETECH-SHH3925g, J06131, NCT00607724
Start Over